Immuneering Corporation (IMRX) on Monday announced a clinical supply agreement with Eli Lilly and Company (LLY) for the ...

Immuneering (IMRX) partners with Eli Lilly to test atebimetinib + olomorasib in a phase 2 trial targeting KRAS G12c-mutant ...

Encouraging early data for IMRX's atebimetinib in RAS-driven cancers sparks interest, but financial and clinical risks ...

Immuneering to evaluate atebimetinib in combination with olomorasib in planned Phase 2 trial in patients with advanced non-small cell lung ...

Investing.com -- Immuneering Corp (NASDAQ:IMRX) stock surged 21.7% Monday after the clinical-stage oncology company announced ...

Shares of Immuneering rose after the company entered into a clinical supply agreement for Eli Lilly's olomorasib drug to support testing of Immuneering's proposed lung-cancer treatment. The stock was ...

Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it has entered into a definitive securities purchase agreement ...

Immuneering Corporation (NASDAQ:IMRX), a clinical-stage biotechnology company specializing in oncology treatments, announced ...

Immuneering said investors agreed to buy roughly 6.3 million shares of its Class A common stock for $3.95 a piece. In lieu of Class A common stock, certain investors will buy pre-funded warrants to ...

Thursday, Immuneering Corporation IMRX revealed topline results from the ongoing Phase 1 portion of its Phase 1/2a trial of IMM-1-104 in advanced RAS-mutant solid tumors. As of February 20, 2024 ...

Immuneering is a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients. The Company’s lead product candidate, IMM ...

Immuneering’s lead product candidate, IMM-1-104, is designed to be a highly selective dual-MEK inhibitor that further disrupts KSR for the treatment of advanced solid tumors in patients ...